Alembic Pharmaceuticals inches up on getting final nod for Alcaftadine Ophthalmic Solution
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Alembic Pharmaceuticals is currently trading at Rs. 1245.00, up by 2.85 points or 0.23% from its previous closing of Rs. 1242.15 on the BSE.
The scrip opened at Rs. 1259.65 and has touched a high and low of Rs. 1259.65 and Rs. 1217.05 respectively. So far 6937 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1285.60 on 08-Aug-2024 and a 52 week low of Rs. 707.50 on 31-Oct-2023.
Last one week high and low of the scrip stood at Rs. 1265.00 and Rs. 1169.70 respectively. The current market cap of the company is Rs. 24416.09 crore.
The promoters holding in the company stood at 69.61%, while Institutions and Non-Institutions held 19.79% and 10.60% respectively.
Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Alcaftadine Ophthalmic Solution, 0.25% (OTC). The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Lastacaft Solution, 0.25%, of AbbVie Inc. (AbbVie). Alcaftadine Ophthalmic Solution, 0.25% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander.
Alembic has a cumulative total of 216 ANDA approvals (189 final approvals and 27 tentative approvals) from USFDA.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
